mTOR and cancer: reason for dancing at the crossroads?

被引：60

作者：

Thomas, GV ^{[1
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Ctr Hlth Sci A7 149, Los Angeles, CA 90095 USA

来源：

CURRENT OPINION IN GENETICS & DEVELOPMENT | 2006年 / 16卷 / 01期

关键词：

D O I：

10.1016/j.gde.2005.12.003

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Recent successes using Gleevec for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors have provided proof that strategies to target signal transduction pathways mutated in human cancers can work. However, the application of this strategy to other cancers has been slow. Central to alleviating this impedance is the molecular characterization of the tumors. There is an urgent need to translate basic scientific findings into relevant, clinically applicable molecular diagnostic assays.

引用

页码：78 / 84

页数：7

共 51 条

[1] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[2] The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation [J].

Beuvink, I ;

Boulay, A ;

Fumagalli, S ;

Zilbermann, F ;

Ruetz, S ;

O'Reilly, T ;

Natt, F ;

Hall, J ;

Lane, HA ;

Thomas, G .

CELL, 2005, 120 (06) :747-759

[3] The TOR pathway: A target for cancer therapy [J].

Bjornsti, MA ;

Houghton, PJ .

NATURE REVIEWS CANCER, 2004, 4 (05) :335-348

[4] Regulation of peptide-chain elongation in mammalian cells [J].

Browne, GJ ;

Proud, CG .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 2002, 269 (22) :5360-5368

[5] TSC2 regulates VEGF through mTOR-dependent and -independent pathways [J].

Brugarolas, JB ;

Vazquez, F ;

Reddy, A ;

Sellers, WR ;

Kaelin, WG .

CANCER CELL, 2003, 4 (02) :147-158

[6] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme [J].

Chang, SM ;

Wen, P ;

Cloughesy, T ;

Greenberg, H ;

Schiff, D ;

Conrad, C ;

Fink, K ;

Robins, HI ;

De Angelis, L ;

Raizer, J ;

Hess, K ;

Aldape, K ;

Lamborn, KR ;

Kuhn, J ;

Dancey, J ;

Prados, MD .

INVESTIGATIONAL NEW DRUGS, 2005, 23 (04) :357-361

[7] Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs [J].

Chang, SM ;

Kuhn, J ;

Wen, P ;

Greenberg, H ;

Schiff, D ;

Conrad, C ;

Fink, K ;

Robins, HI ;

Cloughesy, T ;

De Angelis, L ;

Razier, J ;

Hess, K ;

Dancey, J ;

Prados, MD .

INVESTIGATIONAL NEW DRUGS, 2004, 22 (04) :427-435

[8]

Choe G, 2003, CANCER RES, V63, P2742

[9] Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome [J].

Corradetti, MN ;

Inoki, K ;

Bardeesy, N ;

DePinho, RA ;

Guan, KL .

GENES & DEVELOPMENT, 2004, 18 (13) :1533-1538

[10] Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study [J].

Galanis, E ;

Buckner, JC ;

Maurer, MJ ;

Kreisberg, JL ;

Ballman, K ;

Boni, J ;

Peralba, JM ;

Jenkins, RB ;

Dakhil, SR ;

Morton, RF ;

Jaeckle, KA ;

Scheithauer, BW ;

Dancey, J ;

Hidalgo, M ;

Walsh, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5294-5304

← 1 2 3 4 5 6 →